Trial reportTransfusion medicine (Oxford, England)2026
A quasi-experimental study evaluating the efficacy of crossmatch-matched platelet transfusions in hemato-oncology patients with suspected alloimmune platelet refractoriness: A single-centre experience.
Trial report in Transfusion medicine (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HLA class I antibody distribution and cross-matching strategies in immune platelet transfusion refractory patients: a retrospective cohort study.Frontiers in medicine · 2026Article
- Personalized management of platelet transfusion refractoriness: risk factors, cross-matching, and IVIG strategies.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPlatelet transfusion is essential in managing thrombocytopenia in hemato-oncology patients. This study aimed to determine the prevalence of platelet refractoriness (PR) and to evaluate the efficacy of crossmatch-compatible single-donor platelet (SDP) transfusions in patients with suspected platelet refractoriness. MATERIALS AND
methodsA two-year quasi-experimental study comprised adult and paediatric hemato-oncology patients with two consecutive low corrected count increment (CCI) responses (<7500/μL) following SDP transfusions. Refractory patients with non-immune causes were tried to be excluded as far as possible. Platelet crossmatching was performed using solid-phase red cell adherence (SPRCA) technology. One-hour post-transfusion CCI and percentage platelet recovery (PPR) were evaluated between crossmatch-compatible and incompatible transfusions. Statistical analyses included descriptive statistics as mean ± standard deviation (SD), median with interquartile range (IQR), or frequencies (%). Multivariate regression analysis was used to identify predictors of transfusion response.
resultsAmong 272 SDP transfused patients, 142 (52.2%) were refractory and of them, 101 were eligible for platelet crossmatching. Of the 166 SDP transfusions, 63.4% were crossmatch incompatible. Crossmatch-compatible transfusions yielded significantly higher mean CCI (17 788 vs. 11 913, p = 0.001) and PPR (44.8% vs. 28.7%, p < 0.001). Crossmatching demonstrated high sensitivity (84.8%) and NPV (86.4%) for detecting inadequate responses. Multivariate analysis identified platelet compatibility and age as significant predictors of transfusion efficacy.
conclusionCrossmatch-compatible platelet transfusions significantly improve post-transfusion CCI and PPR in alloimmunised hemato-oncology patients. Crossmatch compatibility and patient age were identified as two independent predictors of adequate early platelet transfusion response (1-h CCI, PPR and platelet increment).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.